LIPID METABOLISM IN ABETALIPOPROTEINEMIA

无β糖蛋白血症中的脂质代谢

• 批准号: 6278164
• 负责人: D ROGER ILLINGWORTH
• 金额: $ 2.86万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278164
• 关键词: abetalipoproteinemias; biological transport; blood lipoprotein transport; clinical research; clinical trials; fatty acids; human subject; lipid metabolism; nutrition related tag; tocopherols

The aims of this ongoing project are to monitor patients with phenotypic abetalipoprotinemia to better delineate nutrient transport (fatty acids, vitamin E) and explore the metabolic consequences and compensatory changes which occur in these patients who lack apoprotein B containing lipoproteins from plasma. GRANT M01RR003340461 This protocol examines the clinical and biochemical efficacy of mevinolin (lovastatin) and its effects upon cholesterol and lipoprotein metabolism. A number of patients will be examined on long-term therapy, for a period in excess of four years, to determine the time related effects of such treatment.

这个正在进行的项目的目的是监测表型为 Abetalipoprotin血症，以更好地描述营养转运(脂肪酸， 维生素E)，并探讨代谢后果和代偿性变化 发生在这些缺乏载脂蛋白B的患者中 血浆中的脂蛋白。 格兰特M01RR003340461 该方案检查了甲维诺林的临床和生化疗效。 (洛伐他汀)及其对胆固醇和脂蛋白代谢的影响。 一些患者将接受为期一段时间的长期治疗。 在超过四年的时间内，以确定与时间相关的影响 治疗。